Trials of ribociclib, palbociclib, abemaciclib, and dalpiciclib in advanced breast cancer have demonstrated the ability to improve progression-free survival in patients with HR+/HER2- advanced breast cancer [8,9,10,11,12,13,14]. Here, ERBB2 is linked to breast carcinoma.